There is now overwhelming evidence to support lowering LDL-c (low-density lipoprotein
cholesterol) to reduce cardiovascular morbidity and mortality. Statins are a class of drugs …

Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid
deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia …

Many patients do not achieve optimal low-density lipoprotein cholesterol (LDL-C) levels with
statins alone; others are unable to tolerate statin therapy. Additional non-statin treatment …

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Statins are a group of lipid-lowering drugs that inhibit cholesterol biosynthesis and have anti-
inflammatory, anti-tumor, and immunomodulatory properties. Several lines of evidence …

In Japan, a super-aged society, deaths from atherosclerotic cardiovascular disease
(ASCVD), especially cardiac diseases including coronary artery disease (CAD) such as …

Statins are the gold-standard treatment for the prevention of primary and secondary
cardiovascular disease, which is the leading cause of mortality worldwide. Despite the safety …

Cholesterol plays an essential role in determining cell membrane physico-chemical
characteristics and functions. A proper membrane structure is critical in pancreatic β-cells for …

Background This meta-analysis evaluated the real-world effectiveness of
onabotulinumtoxinA (BOTOX®), the first preventive treatment FDA-approved specifically for …

Objective To synthesise evidence from exclusively primary prevention data on the
effectiveness of statins for prevention of cardiovascular disease (CVD), including stroke, and …